BRVE vs AGIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BRVE · Braveheart Bio$18.60 ▲ 6.80%
AGIO · Agios Pharmaceuticals$29.41 ▲ 4.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BRVE -37.6%
- AGIO -7.9%
Head to head
| Metric | BRVE | AGIO |
|---|---|---|
| Price | $18.60 | $29.41 |
| Change today | ▲ 6.80% | ▲ 4.03% |
| Market cap | $1.67B | $1.76B |
| Return, 3 months | -32.4% | -9.8% |
| Return, year to date | – | +8.0% |
| Return, 1 year | – | -27.7% |
| P/E (TTM) | – | – |
| P/B | -17.5 | 1.8 |
| P/E percentile vs own 5y | 59th | 59th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +259.3% |
| Net profit growth (YoY) | -3,833.9% | +10.1% |
| Gross margin | – | 92.0% |
| Operating margin | – | -466.8% |
| Net margin | – | -418.2% |
| Return on equity | – | -34.3% |
| Analyst target vs. price | +143.3% | +53.7% |
| Analyst buy share | 100% | 83% |
| RSI (14) | 39 | 38 |
| 30-day volatility | 78.6% | 81.4% |
| Max drawdown, 1 year | -41.9% | -50.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AGIO is the largest of the group by market value.
- BRVE has been the calmest stock over the last 30 days.